vTv Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M |
| Research and development | $17.9M | $11.5M | $13.6M | $12.4M | $13.3M |
| Operating expenses | $32.8M | $25.2M | $25.5M | $24.6M | $25.7M |
| Operating income | -$32.8M | -$24.2M | -$25.5M | -$22.5M | -$21.7M |
| Interest expense | — | $0 | $13,000 | $15,000 | $12,000 |
| Pretax income | -$31.1M | -$22.6M | -$26.0M | -$24.9M | -$17.6M |
| Income tax expense | $0 | $100,000 | $0 | $200,000 | $115,000 |
| Net income | -$27.0M | -$18.5M | -$20.2M | -$19.2M | -$13.0M |
| Balance Sheet | |||||
| Cash and equivalents | $88.9M | $36.7M | $9.4M | $12.1M | $13.4M |
| Current assets | $89.9M | $38.1M | $10.7M | $27.1M | $15.6M |
| Total assets | $89.9M | $38.3M | $11.0M | $33.2M | $25.5M |
| Current liabilities | $6.6M | $5.2M | $10.6M | $7.7M | $8.5M |
| Total liabilities | $25.5M | $24.0M | $29.6M | $27.4M | $10.3M |
| Stockholders' equity | $64.4M | $12.2M | -$24.7M | -$10.7M | -$9.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$25.3M | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Depreciation and amortization | $16,000 | $89,000 | $90,000 | $92,000 | $89,000 |
| Stock-based compensation | $3.8M | $2.8M | $1.6M | $1.3M | $2.4M |
| Capital expenditure | — | $0 | $0 | $21,000 | $0 |
| Free cash flow | — | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 3.9M · Free float 88.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.